Michael LeekChief Executive & Founder at TC BioPharm
Michael has 30 years’ experience in regenerative medicine, during which he progressed 10 different cell-based products from the laboratory into clinic. He founded TC BioPharm in 2014 taking the company into a Nasdaq listing in 2022, developing their lead oncology product to phase 3 multinational clinical trial. Previously he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture expertise which includes management of several FDA/EMEA/MHRA licensed GMP facilities. Additionally, Michael has clinical, regulatory and logistic expertise and he has directly raised over $100m in equity and grant funding. In 2017, Michael received the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award for 2016-2017. Michael is also a Fellow of the Royal Society of Medicine and Honorary Lecturer at the University of Aberdeen, School of Medical Sciences.